1Ishii T,Bruno E,Hoffman R,et al.Involvement of various hematopoietic cell lineage by the JAK2 V617F mutation in polycythemia vera[J].Blood,2006,108(9):3128-3134.
2Schafer AI.Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocytosis[J].Blood,2006,107(11):4214-4222.
3Lippert E,Boissinot M,Kralovics R,et al.The JAK2-V617F mutation is freguently present at diagnosis in patients with essential thrombocy themia and polycythemia vera[J].Blood,2006,108(6):1865-1867.
4Kaushansky K.On the molecular origin of the chronic myeloproliferative disorders:it all makes sense[J].Blood,2005,105(11):4187-4190.
5Wolanskyi AP,Lasho TL,Schwager SM,et al.JAK2V617F mutation in essential thrombocy thaemia:clincal associations and long-term prognostic relevance[J].Br J Haematol,2005,131(2):208-213.
6Tefferi A,Lasho TL,Schwager SM,et al.The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia:lineage specificity and clinical correlates[J].Br J Haematol,2005,131(3):320-328.
7Passamonti F,Rumi E,Pietra D,et al.Relation between JAK2(V617F) mutation status,granulocytic activation,and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders[J].Blood,2006,107(9):3676-3682.
8Popat U,Frost A,Liu E,et al.High levels of circulating DC34 cell dacrocytes,clonal hematopoiesis and JAK2 mutation differential myelofibrosis associated with pulmonary hypertension[J].Blood,2006,107(9):3486-3488.
9Heller PG,Lev PR,Salini JP,et al.JAK2 V617F mutation in platelets from essential thrombocy themia patients:corretation with clinical features and analysis of STAT3 phosphorylation status[J].Eur J Haematol,2006,77(3):210-216.
10Campbell PJ,Baxter EJ,Beer PA,et al.Mutation of JAK2 in the myeloproliferative disorders:timing,clonality studies,cytogenetic associatitions,and role in leukemic transformation[J].Blood,2006,108(10):3548-3555.
